Want to see ANAB full AI Analyst Report?
ANAB Stock Chart & Stats
$67.51
-$0.23(-1.55%)
At close: 4:00 PM EST
$67.51
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$17.11 - $73.30
Previous CloseN/A
Volume154.73K
Average Volume (3M)663.91K
Market Cap
$1.72B
Enterprise Value$1.58K
Total Cash (Recent Filing)$286.45M
Total Debt (Recent Filing)$277.36M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding29,608,480
10 Day Avg. Volume807,592
30 Day Avg. Volume663,912
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$80.67Price Target Upside19.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.52
Revenue Forecast (FY)$109.97M
Bulls Say, Bears Say
Bulls Say
Royalty-focused Business ModelThe April 2026 spin-off structurally repositions AnaptysBio as a royalty-focused, lower-cost franchised company that retained Jemperli/imsidolimab royalties and related collaborations. This durable shift reduces direct R&D burden and increases the proportion of cash flows tied to partner commercialization outcomes, improving long-term cash predictability if partners perform.
Improved Cash GenerationCash generation materially improved in 2025 with positive operating and free cash flow and FCF that aligns with reported earnings, signaling higher earnings quality. This suggests the company can sustainably fund obligations or return capital from royalties rather than relying solely on financing, supporting medium-term financial resilience if milestone timing steadies.
Strengthened Finance Leadership & GovernanceAdding an experienced CFO with performance-based compensation and expanding the board increases financial stewardship and governance capacity during the strategic transition. Stronger management alignment and independent oversight are durable enablers for better capital allocation, partner negotiations and execution of the royalty-focused strategy.
Bears Say
Weakened Balance Sheet / Higher LeverageTrailing results show a meaningful deterioration in capital structure with debt-to-equity above 1x and prior periods of very high leverage. This persistent volatility in balance sheet strength raises refinancing, covenant and liquidity risks, constraining flexibility to manage shocks or opportunistic investments over the medium term.
Revenue And Cash Flow LumpinessRevenue and cash flows depend heavily on timing of partner milestones and license payments, creating durable volatility in top-line and operating cash flow. That makes multi-quarter planning, budgeting, and predictable distributions difficult and increases execution risk because cash availability is not driven by stable product sales but by intermittent partner events.
Net Losses Persist Due To Below-the-line CostsAlthough operating profitability improved, below-the-line items keep reported net income negative, indicating structural drag from non-operating costs, interest or one-time items. Persistent net losses limit retained earnings accumulation and reduce the company's capacity to self-fund initiatives or increase shareholder distributions without relying on partner milestones or external financing.
AnaptysBio News
ANAB FAQ
What was AnaptysBio’s price range in the past 12 months?
AnaptysBio lowest stock price was $17.11 and its highest was $73.30 in the past 12 months.
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $1.72B.
When is AnaptysBio’s upcoming earnings report date?
AnaptysBio’s upcoming earnings report date is Aug 10, 2026 which is in 20 days.
How were AnaptysBio’s earnings last quarter?
AnaptysBio released its earnings results on May 12, 2026. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$0.644 by -$1.196.
Is AnaptysBio overvalued?
According to Wall Street analysts AnaptysBio’s price is currently Undervalued.
Does AnaptysBio pay dividends?
AnaptysBio does not currently pay dividends.
What is AnaptysBio’s EPS estimate?
AnaptysBio’s EPS estimate is -0.13.
How many shares outstanding does AnaptysBio have?
AnaptysBio has 29,608,480 shares outstanding.
What happened to AnaptysBio’s price movement after its last earnings report?
AnaptysBio reported an EPS of -$1.84 in its last earnings report, missing expectations of -$0.644. Following the earnings report the stock price went down -4.414%.
Which hedge fund is a major shareholder of AnaptysBio?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.67 (19.49% Upside)
$80.67 (19.49% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 135.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.89%
Trailing 12-Months
Company Description
AnaptysBio
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$80.67
▲(19.49% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
―
Ownership Overview
2.28% Insiders
11.74% Mutual Funds
0.11% Other Institutional Investors
72.41% Public Companies and
Individual Investors